Hepatorenal Syndrome Market
Number of pages: 100 | Report Format: PDF | Published date: April 28, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 14.04 billion |
|
Revenue Forecast in 2031 |
US$ 24.34 billion |
|
CAGR |
6.3% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Treatment, Type, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global hepatorenal syndrome was valued at US$ 14.04 billion in 2022 and is expected to register a revenue CAGR of 6.3% to reach US$ 24.34 billion by 2031.
Hepatorenal Syndrome Market Fundamentals
Hepatorenal syndrome (HRS) is a rare type of functional renal failure caused by decreased renal blood flow that often occurs in histologically normal kidneys. It is a serious consequence of advanced liver disease primarily affecting cirrhotic individuals with ascites. The prognosis is bleak, with survival often measured in weeks to months. Because there are no known biomarkers, hepatorenal syndrome is diagnosed using a mix of clinical and laboratory criteria. Several therapy options are available, and early diagnosis and treatment offer the highest chance of survival. Additionally, the most frequently recognized explanation for the pathophysiology of hepatorenal syndrome is the peripheral arterial vasodilation theory, which suggests that splanchnic vasodilation caused by portal hypertension with cirrhosis is the initiating element for the development of hepatorenal syndrome.
The International Ascites Club (IAC) divides hepatorenal syndrome into type 1 and type 2. Type 1 hepatorenal syndrome is a rapidly increasing renal impairment defined by a blood creatinine level of more than 2.5 mg/dL or more than 226 mol/L doubling in less than two weeks. Type 2 hepatorenal syndrome is characterized by significant renal impairment (serum creatinine > 1.5 and up to 2.5 mg/dL or > 133 and 226 mol/L) with a steadily progressive course that lasts weeks to months. First and foremost, hepatorenal syndrome entails restoring euvolemia while discontinuing any nephrotoxic medications. HRS is actively treated medically by splanchnic vasoconstriction, which leads to increased systemic vascular resistance and mean arterial pressure. This lowers the renin-angiotensin-aldosterone system (RAAS) and the SNS via a counter-regulatory mechanism. As a result, renal vasoconstriction is reduced, and renal blood flow is improved. A variety of medical therapy combinations accomplishes this.
The hepatorenal syndrome affects around 4% of individuals with decompensated liver failure. Most of these individuals suffer from portal hypertension caused by alcoholic hepatitis, cirrhosis, or metastatic malignancies. In individuals with decompensated liver disease, the cumulative likelihood of developing HRS at one year is 18% and 39% at five years. Patients with hyponatremia and high plasma renin activity were the most at risk. One-third of individuals with spontaneous bacterial peritonitis will develop HRS.
[14]
Hepatorenal Syndrome Market Dynamics
Growing special designation from regulatory agencies and developments in hepatorenal syndrome treatment facilities drive market expansion. Rising healthcare infrastructure development expenditure, growing unmet treatment needs, increased need for improved and effective therapies, surging geriatric population base globally, increasing government initiatives & funding for therapy development, and increasing the rate of strategic collaboration among market players are other factors fostering the market growth. Another indirect driver providing attractive market growth potential is the rising consumption of unhealthy foods and beverages like alcohol.
Furthermore, partnerships are anticipated to increase the possibilities of developing a comprehensive therapy for the hepatorenal syndrome, enhancing patient survival rates and propelling the hepatorenal syndrome treatment market forward. Growing research into therapies for treating hepatorenal syndrome also helps the market's development, with a promise to continue contributing to growth in the future years. Terlipressin, an experimental drug for treating type 1 hepatorenal syndrome, was launched in May 2019 by Mallinckrodt, a worldwide specialty pharmaceutical firm. Albumin's widespread use is also fueling market expansion. Healthcare professionals recommend a combination of albumin and antibiotics as a cost-effective therapy for hepatorenal syndrome with cirrhosis.
However, it has been shown that treating hepatorenal syndrome places an individual under considerable economic pressure, impeding market expansion. However, a rising number of research activities are being conducted to treat hepatorenal syndrome employing medicines, which is expected to give the hepatorenal syndrome market an opportunity over the forecast period.
Hepatorenal Syndrome Market Ecosystem
The global hepatorenal syndrome market is analyzed from the following perspectives by treatment, type, end user, and region.
Hepatorenal Syndrome Market by Treatment
[25]
The global hepatorenal syndrome market is segmented into therapeutics and surgical treatment based on the treatment. The therapeutics segment is further segmented into Vasopressin analogues, antibiotics, and others, and surgical treatment is also segmented into liver transplantation, surgical shunting, renal replacement therapy, and others.
The therapeutics segment will likely show lucrative market growth during the forecast period. The therapeutics market is likely to increase more rapidly as people choose to take medications rather than endure surgery. Furthermore, expanding the pharmaceuticals' fast track and orphan designations is strengthening the segment. Several pharmaceuticals have acquired orphan drug status, accelerating their approval process, which can drive the therapeutics segment's growth. For example, BioVie Inc. reported in November 2018 that the FDA had given Orphan medication designation to their Terlipressin medication for treating hepatorenal syndrome. The classification of orphan pharmaceuticals entitles producers to various benefits, including tax deductions for eligible clinical trials and seven years of commercial exclusivity following regulatory clearance.
Hepatorenal Syndrome Market by Type
Based on the type, the global hepatorenal syndrome market is segmented into Type 1 hepatorenal syndrome and Type 2 hepatorenal syndrome.
Type 1 hepatorenal syndrome showed significant growth during the forecast period due to the increasing prevalence of type 1 hepatorenal syndrome. Type I is a fast-progressing illness that leads to renal failure; type II is a more gradual progression that takes weeks to months. Type 1 HRS has a poor prognosis, with 80% death after two weeks. Renal function may recover on its own when liver function improves. This is most commonly seen in acute liver failure or alcoholic hepatitis or after abrupt decompensation on a cirrhotic background. These individuals are frequently jaundiced and have severe coagulopathy. A combination of hepatic and renal failure and variceal hemorrhage frequently causes mortality.
Hepatorenal Syndrome Market by End User
Based on the end users, the global hepatorenal syndrome market is segmented into hospitals & clinics, ambulatory surgical centers, academic & research institutes, and others.
Hospitals and clinics are projected to hold a substantial market revenue share throughout the forecast period. The dominant position of hospitals and clinics is due to the high footfall of hospital patients worldwide that efficiently support surgical interventions for hepatorenal syndrome. Hospitals and clinics have sophisticated laboratories and systems for efficient diagnosis & treatment of hepatorenal syndrome. Hospitals and clinics also house specialized physicians and care staff to offer the best healthcare for hepatorenal syndrome management. However, due to the growing cost and social burdens on the healthcare system, there is a growing need for developing novel treatments for hepatorenal syndrome. This is supporting the rapid growth of the academic and research institutes segment.
Hepatorenal Syndrome Market by Region
Based on region, the global hepatorenal syndrome market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America will likely lead the global market throughout the projected period. The presence of important players, strong healthcare infrastructure, and rising frequency of severe liver disease and cirrhosis are some of the key factors responsible for its huge position in the market. Furthermore, favorable government efforts and an increase in the number of research collaborations are likely to fuel market expansion. Because of favorable healthcare regulations, a large number of patients, and a developed healthcare sector, the United States has the largest share in this region. According to the US Department of Health and Human Services, one in every 400 individuals in the US had cirrhosis in 2018. According to data, this country's expanding patient pool and disposable money promote the region's market growth.
Additionally, hepatorenal syndrome market companies are increasing efforts to bring innovative therapeutic options to hepatorenal syndrome patients in the United States. However, it has been shown that there is a growing demand in the United States for cost-effective therapy alternatives for diagnosing hepatorenal syndrome. Costly hepatorenal syndrome therapies have caused a financial strain for patients. This has damaged the credibility of outcomes because patients lack access to cost-effective and effective treatment choices.
During the projection period, Asia Pacific is expected to increase significantly and have the highest revenue CAGR. This is due to increased healthcare infrastructure construction costs, an increase in renal disease cases, an increasing geriatric population base, and increased research and development efforts for treating and managing liver illnesses. Companies in the hepatorenal syndrome therapy industry are conducting comprehensive research to determine the number of hospitals that provide more expensive therapies. It is especially true compared to hospitals in Asia Pacific's underdeveloped countries. For example, it has been discovered that hepatorenal syndrome therapy costs in India are less expensive than the economic evaluation of treatment supplied in Brazil. Companies in the hepatorenal syndrome therapy market are expanding R&D to design techniques that lower the cost burden on patients.
Hepatorenal Syndrome Competitive Landscape
Strategic cooperation between important pharmaceutical manufacturers and companies with medicines in clinical trials to speed up the research and development process is anticipated to benefit thousands of people suffering from the hepatorenal syndrome. Collaborations are expected to drive the hepatorenal syndrome therapy market by fueling fresh product releases. Some of the prominent market players in the global hepatorenal syndrome market include:
Hepatorenal Syndrome Strategic Development
Hepatorenal syndrome (HRS) is a rare type of functional renal failure caused by decreased renal blood flow that often occurs in histologically normal kidneys. It is a serious consequence of advanced liver disease primarily affecting cirrhotic individuals with ascites.
The estimated market size of the hepatorenal syndrome market in 2031 will be US$ 24.34 billion.
The revenue CAGR of the hepatorenal syndrome market during the forecast period will be 6.3%.
Some prominent global hepatorenal syndrome market players include Mallinckrodt Pharmaceuticals, Cumberland Pharmaceuticals Inc., and Edwards Lifesciences Corporation.
The therapeutics segment led the global hepatorenal syndrome market.
*Insights on financial performance are subject to the availability of information in the public domain